New Drug Combination for Advanced Liver Cancer After First Treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments (benmelstobart, anlotinib, and SBRT radiation) for patients with advanced liver cancer (hepatocellular carcinoma) whose cancer did not respond to or worsened after their first targeted therapy. The goal is to see if this new combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that has spread to a limited number of places (no more than 2 organs, maximum 5 spots total)
- Your cancer did not respond to or got worse after your first-line targeted therapy or immunotherapy treatment
- Your liver function is reasonably well-preserved (Child-Pugh score of 7 or lower)
- Your overall health status is good enough for treatment (ECOG score of 0 or 1, meaning you can do normal activities or have minor limitations)
- Your blood counts, liver, and kidney function tests are within acceptable ranges (checked within 7 days before starting)
- You are expected to live at least 12 weeks from the start of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests a combination of radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy drug (apatinib) to shrink liver cancer that cannot be removed with surgery. The goal is to make the cancer small enough for surgery later.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.